Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DOMINIC JOHN TITONE

Allopathic & Osteopathic Physicians Internal Medicine Critical Care Medicine

NPI
1184816159
CMS profile
1109025
Location
LAKEWOOD, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$41.92

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $41.92 2

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Regeneron Healthcare Solutions, Inc. $22.50 1
GlaxoSmithKline, LLC. $19.42 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DOMINIC JOHN TITONE

NPI 1184816159 · CMS profile ID 1109025

Allopathic & Osteopathic Physicians / Internal Medicine / Critical Care Medicine

LAKEWOOD, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1184816159?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DOMINIC JOHN TITONE, NPI 1184816159, CMS profile ID 1109025. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1184816159?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). DOMINIC JOHN TITONE, NPI 1184816159, CMS profile ID 1109025. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1184816159?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
DOMINIC JOHN TITONE, NPI 1184816159, CMS profile ID 1109025, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1184816159?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $41.92 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $19.4206/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944583311 CMS
Regeneron Healthcare Solutions, Inc. $22.5002/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927446671 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $166.08 11
PY2020 $61.33 4
PY2021 $56.81 4
PY2022 $41.92 2
PY2023 $1,906.18 9
PY2024 $317.03 11
PY2025 $2,082.80 11

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $428,478.86 96
PY2024 Principal investigator $715,381.10 49
PY2023 Principal investigator $766,726.52 505

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

96 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $600.00 12/24/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211640212
Principal investigator 1 ModernaTX, Inc. $6,848.55 12/17/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252956587
Principal investigator 1 ModernaTX, Inc. $103,970.25 12/05/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252956601
Principal investigator 1 ModernaTX, Inc. $4,116.82 12/01/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252956593
Principal investigator 1 Genentech, Inc. $3,800.00 11/14/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211640144
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 11/05/2025 Non-covered Recipient Entity
CRITICAL CARE PULMONARY AND SLEEP ASSOCIATES
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192185701
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $85.06 11/01/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220817494
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $15.40 11/01/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220817496
Principal investigator 1 ModernaTX, Inc. $5,001.75 10/22/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252956577
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 10/01/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220783753
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 10/01/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220817498
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $42.00 10/01/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220817500
Principal investigator 1 ModernaTX, Inc. $8,002.80 09/24/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252956581
Principal investigator 1 SANOFI US SERVICES INC. $26,750.00 09/15/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype No dispute reported 06/30/2026 1226139772
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 09/03/2025 Non-covered Recipient Entity
CRITICAL CARE PULMONARY AND SLEEP ASSOCIATES
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192185692
Principal investigator 1 ModernaTX, Inc. $6,002.10 09/02/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252956595
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 09/01/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220783751
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $42.00 09/01/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220817534
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 09/01/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220817536
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,800.00 08/15/2025 Non-covered Recipient Entity
Qcare Site Services, Inc Avacare
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220812908
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,135.00 08/06/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA) No dispute reported 06/30/2026 1185549049
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 08/01/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220783749
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $42.00 08/01/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220817530
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 08/01/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220817532
Principal investigator 1 ModernaTX, Inc. $3,001.05 08/01/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252956589
Principal investigator 1 Genentech, Inc. $750.00 07/30/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211639917
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,800.00 07/26/2025 Non-covered Recipient Entity
Qcare Site Services, Inc Avacare
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220812995
Principal investigator 1 Genentech, Inc. $729.00 07/25/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211639984
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,450.00 07/16/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 1185549055
Principal investigator 1 Genentech, Inc. $900.00 07/16/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211639792
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $19,500.00 07/11/2025 Non-covered Recipient Entity
QCARE SITE SERVICES
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244050622
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,000.00 07/11/2025 Non-covered Recipient Entity
QCARE SITE SERVICES
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244050624
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,000.00 07/11/2025 Non-covered Recipient Entity
QCARE SITE SERVICES
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244050626
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 07/11/2025 Non-covered Recipient Entity
QCARE SITE SERVICES
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244050628
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 07/11/2025 Non-covered Recipient Entity
QCARE SITE SERVICES
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244050630
Principal investigator 1 Genentech, Inc. $372.00 07/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211640041
Principal investigator 1 ModernaTX, Inc. $9,557.03 07/02/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252956591
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 07/01/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220783747
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 07/01/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220817526
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $42.00 07/01/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220817528
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,195.00 06/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Phase 2a Randomised Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA No dispute reported 06/30/2026 1185549045
Principal investigator 1 Genentech, Inc. $9,268.00 06/18/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211639774
Principal investigator 1 Genentech, Inc. $2,754.00 06/04/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211589662
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 06/01/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220783745
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 06/01/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220817522
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $42.00 06/01/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220817524
Principal investigator 1 Genentech, Inc. $750.00 05/30/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211589626
Principal investigator 1 ModernaTX, Inc. $3,001.05 05/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252956597
Principal investigator 1 AstraZeneca Pharmaceuticals LP $43,262.41 05/14/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185549053
Principal investigator 1 Genentech, Inc. $1,500.00 05/14/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211589889
Principal investigator 1 Genentech, Inc. $1,438.00 05/07/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211589575
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $179.90 05/06/2025 Non-covered Recipient Entity
QCARE SITE SERVICES
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244050714
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 05/01/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220783743
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 05/01/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220817518
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $42.00 05/01/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220817520
Principal investigator 1 ModernaTX, Inc. $8,118.23 04/23/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252956575
Principal investigator 1 ModernaTX, Inc. $3,250.00 04/18/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252956579
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 04/01/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220783741
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 04/01/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220817514
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $42.00 04/01/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220817516
Principal investigator 1 ModernaTX, Inc. $6,553.57 04/01/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252956583
Principal investigator 1 Genentech, Inc. $1,438.00 03/28/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211589275
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 03/25/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220783731
Principal investigator 1 Boehringer Ingelheim International GmbH $179.82 03/25/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220783733
Principal investigator 1 Boehringer Ingelheim International GmbH $657.00 03/25/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220783735
Principal investigator 1 Boehringer Ingelheim International GmbH $98.55 03/25/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220783737
Principal investigator 1 Genentech, Inc. $1,438.00 03/21/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211589368
Principal investigator 1 Genentech, Inc. $150.00 03/14/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211589470
Principal investigator 1 GlaxoSmithKline, LLC. $12,265.00 03/14/2025 Non-covered Recipient Entity
CRITICAL CARE PULMONARY AND SLEEP ASSOCIATES
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192185697
Principal investigator 1 GlaxoSmithKline, LLC. $2,115.00 03/14/2025 Non-covered Recipient Entity
CRITICAL CARE PULMONARY AND SLEEP ASSOCIATES
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192185705
Principal investigator 1 ModernaTX, Inc. $35,185.39 03/12/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252956599
Principal investigator 1 Genentech, Inc. $2,876.00 03/05/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211589332
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 03/01/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220783729
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $42.00 03/01/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220817510
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 03/01/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220817512
Principal investigator 1 AstraZeneca Pharmaceuticals LP $38,357.00 02/26/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 No dispute reported 06/30/2026 1185549051
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 02/25/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
Ph2 PoC in IPF No dispute reported 06/30/2026 1220783755
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 02/25/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
Ph2 PoC in IPF No dispute reported 06/30/2026 1220783757
Principal investigator 1 Boehringer Ingelheim International GmbH $366.42 02/25/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
Ph2 PoC in IPF No dispute reported 06/30/2026 1220783759
Principal investigator 1 Boehringer Ingelheim International GmbH $124.38 02/25/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
Ph2 PoC in IPF No dispute reported 06/30/2026 1220783761
Principal investigator 1 Boehringer Ingelheim International GmbH $10.08 02/25/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
Ph2 PoC in IPF No dispute reported 06/30/2026 1220783763
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 02/25/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
Ph2 PoC in IPF No dispute reported 06/30/2026 1220783765
Principal investigator 1 Genentech, Inc. $1,438.00 02/05/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211589024
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 02/01/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220783727
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $42.00 02/01/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220817506
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 02/01/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220817508
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,798.71 01/29/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185549057
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,942.00 01/24/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
A Phase 2a Randomised Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA No dispute reported 06/30/2026 1185549047
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,500.00 01/17/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Randomized, Participant- and Investigator-blinded, Placebo-controlled Study to Investigate Efficacy, Safety, and Tolerability of LTP001 in Participants With Pulmonary Arterial Hypertension No dispute reported 06/30/2026 1190311191
Principal investigator 1 ModernaTX, Inc. $1,250.00 01/15/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252956585
Principal investigator 1 Genentech, Inc. $10,066.00 01/14/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211589107
Principal investigator 1 Genentech, Inc. $750.00 01/14/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211589317
Principal investigator 1 ModernaTX, Inc. $500.00 01/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252956603
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 01/01/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220783739
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 01/01/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220817502
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $42.00 01/01/2025 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220817504